Among patients with BC not expressing hormone receptors (8 HER-2 negative and 3 HER-2 positive), CBR was 27%, and median PFS was 4.3 months, but the ORR was 0% (0/11) [68]. This evidence concerns the gene ERBB2 and breast cancer.